Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | CTSH | P09668 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | LIN28A | Q9H9Z2 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497135 | 0.82 | CAPN1 (0.60) | CAPN1CTSLCTSBCTSHCTSD | |
| SCHEMBL497811 | 0.81 | CAPN1 (0.47) | CAPN1CTSLCTSBCTSHCTSD | |
| SCHEMBL3323022 | 0.80 | RXFP1 (0.47) | CAPN1CTSLCTSBCTSHCTSD | |
| SCHEMBL497311 | 0.78 | CAPN1 (0.51) | CAPN1CTSLCTSBCTSHCTSD | |
| SCHEMBL3324591 | 0.72 | CAPN1 (0.62) | CAPN1CTSLCTSBCTSHCTSD | |
| SCHEMBL11610676 | 0.66 | KDM4E (0.55) | RXFP1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29822237 | 0.66 | KDM4E (0.66) | RXFP1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4311940 | 0.66 | KDM4E (0.66) | RXFP1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5471126 | 0.62 | RAB9A (0.65) | KDM4ENPC1RAB9AALDH1A1POLB | |
| SCHEMBL12919798 | 0.62 | RAB9A (0.56) | RXFP1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106071-B2 | Compositions for treating hyperproliferative vascular disorders and cancers | BIOBUD CO., LTD. (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106071-B2 | Compositions for treating hyperproliferative vascular disorders and cancers | BIOBUD CO., LTD. (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106071-B2 | Compositions for treating hyperproliferative vascular disorders and cancers | BIOBUD CO., LTD. (KR) | 2012-01-31 | — | — | US | disclosed |
| US-20100120849-A1 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers | BIOBUD CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120849-A1 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers | BIOBUD CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120849-A1 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers | MKI67, MYLK, PCNA | CAPN1 4329/4885CTSL 4783/4885CTSB 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.